New Regulations Introduce Mandatory Substitution Rules for BiologicsFri 6th Mar, 2026Effective from April, comprehensive changes to the regulations governing the substitution of biologic medicines, specifically biosimilars, will be implemented in Germany. The Joint Federal Committee (G-BA) has clarified the criteria for the mandatory substitution of these complex drugs, a move that is expected to have significant implications for pharmacies, healthcare providers, and patients. Under the revised framework, pharmacies are now required to substitute prescribed biologic medications with approved biosimilars when certain conditions are met. Substitution is permitted not only between a reference biologic and its biosimilars but also among biosimilars that reference the same original biologic. Next Steps for Pharmacies and Healthcare ProvidersPharmacies will need to carefully review prescriptions for biologics, ensuring all substitution conditions are met before dispensing an alternative.

Source: The Munich Eye March 06, 2026 22:12 UTC